Felty's syndrome and hypofibrinogenemia: an unusual target for anti-cyclic citrullinated peptide antibodies?

References

• Dearden C. Large granular lymphocytic leukaemia pathogenesis and management. Br J Haematol. 2011; 152(3):273–83.
   PubMed Web of Science ®Google Scholar
• Shipley E, Heraud A, Hennette A, Vernhes JP. Efficacy of rituximab in Felty’s syndrome. Joint Bone Spine. 2008; 75(5):621–2.
   PubMed Web of Science ®Google Scholar
• Lekharaju V, Chattopadhyay C. Efficacy of rituximab in Felty’s syndrome. Ann Rheum Dis. 2008; 67(9):1352.
   PubMed Web of Science ®Google Scholar
• Salama A, Schneider U, Dorner T. Beneficial response to rituximab in a patient with haemolysis and refractory Felty syndrome. Ann Rheum Dis. 2008; 67(6):894–95.
   PubMed Web of Science ®Google Scholar
• Sokol L, Loughran TP, Jr. Large granular lymphocyte leukemia. Oncologist. 2006: 11(3):263–73.
   PubMed Web of Science ®Google Scholar
• Watters RJ, Liu X, Loughran TP. T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias. Leuk Lymphoma. 2011;52(12):2217–25.
   PubMed Web of Science ®Google Scholar
• Liu X, Loughran TP, Jr. The spectrum of large granular lymphocyte leukemia and Felty’s syndrome. Curr Opin Hematol. 2011; 18(4): 254–9.
   PubMed Web of Science ®Google Scholar
• Zendman AJ, van Venrooij WJ, Pruijn GJ. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology (Oxford). 2006; 45(1):20–25.
   PubMed Web of Science ®Google Scholar
• Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L, et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis. 2005; 64(8): 1199–204.
   PubMed Web of Science ®Google Scholar
• Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays. 2003; 25(11):1106–18.
   PubMed Web of Science ®Google Scholar
• Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004; 50(11):3485–94.
   PubMed Web of Science ®Google Scholar
• Chapuy-Regaud S, Sebbag M, Baeten D, Clavel C, Foulquier C, De Keyser F, et al. Fibrin deimination in synovial tissue is not specific for rheumatoid arthritis but commonly occurs during synovitides. J Immunol. 2005; 174(8):5057–64.
   PubMed Web of Science ®Google Scholar
• Ioan-Facsinay A, el-Bannoudi H, Scherer HU, van der Woude D, Menard HA, Lora M, et al. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis. 2011; 70(1):188–93.
   PubMed Web of Science ®Google Scholar
• Abstracts of the 23rd European Workshop for Rheumatology Research, Marseille, France, 27 February – 2 March 2003. Arthritis Res Ther. 2003; 5(Suppl 1):1–116.
   Google Scholar
• Takizawa Y, Suzuki A, Sawada T, Ohsaka M, Inoue T, Yamada R, et al. Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis. 2006; 65(8):1013–20.
   PubMed Web of Science ®Google Scholar
• Sanchez-Pernaute O, Largo R, Calvo E, Alvarez-Soria MA, Egido J, Herrero-Beaumont G. A fibrin based model for rheumatoid synovitis. Ann Rheum Dis. 2003; 62(12):1135–38.
   PubMed Web of Science ®Google Scholar
• Zhao X, Okeke NL, Sharpe O, Batliwalla FM, Lee AT, Ho PP, et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther. 2008; 10(4):R94.
   Web of Science ®Google Scholar
• Nakayama-Hamada M, Suzuki A, Furukawa H, Yamada R, Yamamoto K. Citrullinated fibrinogen inhibits thrombin-catalysed fibrin polymerization. J Biochem. 2008; 144(3):393–8.
   PubMed Web of Science ®Google Scholar
• Gallistl S, Mangge H, Neuwirth G, Muntean W. Activation of the haemostatic system in children with juvenile rheumatoid arthritis correlates with disease activity. Thromb Res. 1998; 92(6):267–72.
   PubMed Web of Science ®Google Scholar
• Abou-Raya S, Abou-Raya A, Naim A, Abuelkheir H. Rheumatoid arthritis, periodontal disease and coronary artery disease. Clin Rheumatol. 2008; 27(4):421–7.
   PubMed Web of Science ®Google Scholar
• McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford). 2001; 40(6):640–4.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum. 2004; 50(11):3444–9.
   PubMed Web of Science ®Google Scholar
• Yildirim K, Karatay S, Melikoglu MA, Gureser G, Ugur M, Senel K. Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci. 2004; 34(4):423–6.
   PubMed Web of Science ®Google Scholar
• Rooney T, Scherzer R, Shigenaga JK, Graf J, Imboden JB, Grunfeld C. Levels of plasma fibrinogen are elevated in well-controlled rheumatoid arthritis. Rheumatology (Oxford). 2011; 50(8):1458–65.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Huang AJ, Landman SL, Nicholson SC, Silverstein SC. Elastase-mediated fibrinogenolysis by chemoattractant-stimulated neutrophils occurs in the presence of physiologic concentrations of antiproteinases. J Exp Med. 1987; 166(6):1836–50.
   PubMed Web of Science ®Google Scholar
• Adams SA, Kelly SL, Kirsch RE, Robson SC, Shephard EG. Role of neutrophil membrane proteases in fibrin degradation. Blood Coagul Fibrinolysis. 1995; 6(8):693–702.
   PubMed Web of Science ®Google Scholar
• Auger I, Roudier C, Guis S, Balandraud N, Roudier J. HLA-DRB1*0404 is strongly associated with anticalpastatin antibodies in rheumatoid arthritis. Ann Rheum Dis. 2007; 66(12):1588–93.
   PubMed Web of Science ®Google Scholar
• Charpin C, Martin M, Balandraud N, Roudier J, Auger I. Autoantibodies to BRAF, a new family of autoantibodies associated with rheumatoid arthritis. Arthritis Res Ther. 2010; 12(5):R194.
   Web of Science ®Google Scholar
• Auger I, Martin M, Balandraud N, Roudier J. Rheumatoid arthritis-specific autoantibodies to peptidyl arginine deiminase type 4 inhibit citrullination of fibrinogen. Arthritis Rheum. 2010; 62(1):126–31.
   PubMed Web of Science ®Google Scholar
• Chapuy-Regaud S, Nogueira L, Clavel C, Sebbag M, Vincent C, Serre G. IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clin Exp Immunol. 2005, 139(3):542–50.
   PubMed Web of Science ®Google Scholar
• Sebbag M, Moinard N, Auger I, Clavel C, Arnaud J, Nogueira L, et al. Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol. 2006; 36(8):2250–63.
   PubMed Web of Science ®Google Scholar